BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11420602)

  • 1. The involvement of sphingolipids in multidrug resistance.
    Sietsma H; Veldman RJ; Kok JW
    J Membr Biol; 2001 Jun; 181(3):153-62. PubMed ID: 11420602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingolipid metabolism enzymes as targets for anticancer therapy.
    Kok JW; Sietsma H
    Curr Drug Targets; 2004 May; 5(4):375-82. PubMed ID: 15134220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.
    Salustiano EJ; da Costa KM; Freire-de-Lima L; Mendonça-Previato L; Previato JO
    J Biol Chem; 2020 May; 295(19):6457-6471. PubMed ID: 32229586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells.
    Kok JW; Veldman RJ; Klappe K; Koning H; Filipeanu CM; Müller M
    Int J Cancer; 2000 Jul; 87(2):172-8. PubMed ID: 10861470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide glycosylation potentiates cellular multidrug resistance.
    Liu YY; Han TY; Giuliano AE; Cabot MC
    FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
    Hajj C; Becker-Flegler KA; Haimovitz-Friedman A
    Biol Chem; 2015 Jun; 396(6-7):669-79. PubMed ID: 25719313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids in neuroblastoma: their role in drug resistance mechanisms.
    Sietsma H; Dijkhuis AJ; Kamps W; Kok JW
    Neurochem Res; 2002 Aug; 27(7-8):665-74. PubMed ID: 12374201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin induces apoptosis of multidrug-resistant human leukemia HL60 cells by complex pathways leading to ceramide accumulation.
    Shakor AB; Atia M; Ismail IA; Alshehri A; El-Refaey H; Kwiatkowska K; Sobota A
    Biochim Biophys Acta; 2014 Dec; 1841(12):1672-82. PubMed ID: 25240837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Onus of Sphingolipid Enzymes in Cancer Drug Resistance.
    Morad SAF; Cabot MC
    Adv Cancer Res; 2018; 140():235-263. PubMed ID: 30060811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.
    Kartal Yandım M; Apohan E; Baran Y
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):13-20. PubMed ID: 23073611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids and response to chemotherapy.
    Dimanche-Boitrel MT; Rebillard A
    Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains.
    Hinrichs JW; Klappe K; van Riezen M; Kok JW
    J Lipid Res; 2005 Nov; 46(11):2367-76. PubMed ID: 16150833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?
    Lee WK; Kolesnick RN
    Cell Signal; 2017 Oct; 38():134-145. PubMed ID: 28687494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
    Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
    Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1).
    Wegner MS; Gruber L; Mattjus P; Geisslinger G; Grösch S
    BMC Cancer; 2018 Feb; 18(1):153. PubMed ID: 29409484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
    Gencer EB; Ural AU; Avcu F; Baran Y
    Ann Hematol; 2011 Nov; 90(11):1265-75. PubMed ID: 21455605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipid metabolism and drug resistance in hematological malignancies.
    Gouaze-Andersson V; Cabot MC
    Anticancer Agents Med Chem; 2011 Nov; 11(9):891-903. PubMed ID: 21707483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy.
    Fox TE; Han X; Kelly S; Merrill AH; Martin RE; Anderson RE; Gardner TW; Kester M
    Diabetes; 2006 Dec; 55(12):3573-80. PubMed ID: 17130506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.
    Olshefski RS; Ladisch S
    Int J Cancer; 2001 Jul; 93(1):131-8. PubMed ID: 11391632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of ceramide and sphingolipid metabolism in tumors: potential modulation of chemotherapy.
    Modrak DE
    Methods Mol Med; 2005; 111():183-94. PubMed ID: 15911980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.